Skip to content


  • Correction
  • Open Access

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Contributed equally
Cardiovascular Diabetology201817:38

  • Received: 19 February 2018
  • Accepted: 19 February 2018
  • Published:

The original article was published in Cardiovascular Diabetology 2017 16:65

Correction to: Cardiovasc Diabetol (2017) 16:65

Following publication of the original article [1] the authors reported that the first affiliation (“Medical Center of the Graduate School, Nanchang University, China”) had been added in error, and that the correct author information is as given in this erratum.



Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Nephrology, The Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, Zip Code: 330006, People’s Republic of China


  1. Zou H, Zhou B, Gaosi X. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16:65. ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s) 2018